Summary
The authors evaluated the clinical significance of anti-ClOO, anti-GOR and anti-CP9 in hepatitis C virus (HCV)-related liver disease in two populations: 459 healthy subjects and 385 patients with chronic liver disease (CLD). Previously we reported high rates of mortality and morbidity (5.3%) of CLD in subjects in Saga, Japan. This was ascribed to the high prevalence (10.8%) of anti-HCV among randomized populations, as detected by the C100 ELISA test system, as compared with a finding of 2–3% in Japanese blood donors in the same decade. The incidence of anti-ClOO, anti-GOR and anti-CP9 detected by ELISA test system in the healthy population currently surveyed was 17.0%, 19.2% and 32.0% respectively, as compared with 75.3%, 60.3% and 73.0% respectively, in those with CLD. The incidence of positivity for at least one of the three antibodies was high (36.4%) among healthy subjects, and even higher (86.5%) among the patients with CLD. In the healthy subjects, incidence of positivity increased with age. Thé healthy and CLD populations differed in the proportion of cases positive for all three antibodies vs. those positive for at least one antibody: healthy subjects, 52/167, 31.1%, vs. CLD patients, 197/333, 59.2%; P<0.01. Among the anti-C100-positive healthy cases, these was a significantly high level of AST, ALT, ZTT and γ GTP compared with negative cases, with or without anti-GOR and anti-CP9 (P<0.01-0.05). These observations suggest that the presence of anti-ClOO may be related to the active state of HCV-related liver disease. In addition, the presence of anti-GOR and anti-CP9 suggest that the patients is an asymptomatic carrier of HCV or is recovering from an HCV infection.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood borne nonA nonB hepatitis genome. Science 1989;244:359–364.
Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human nonA nonB hepatitis. Science 1989;244:362–364.
Weiner AJ, Kuo G, Bradley DW, et al. Detection of hepatitis C viral sequences in nonA, nonB hepatitis. Lancet 1990;335:l-3.
Ikeda Y, Toda G, Kurokawa K, et al. Antibody to Superoxide dismutase, autoimmune hetatitis, and antibody test for hepatitis C virus. Lancet 1990;335:1345–1346.
McFarlane IJ, Smith HM, Johnson PJ, et al. Hepatitis C virus anti bodies in chronic active hepatitis: pathogenic factor or false-positive result? Lancet 1990;335:754–757.
Okamoto H, Munekata E, Tsuda F, et al. Enzyme-Linked Immunosorbent assay for antibodies against the capsid protein of hepatitis C virus with a synthetic oligopeptide. Japan J Exp Med 1990;60:223–233.
Mishiro S, Hoshi Y, Takeda K, et al. Non-A, Non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet 1990;336:1400–1403.
Setoguchi Y, Yamamoto K, Ozaki I, et al. Prevalence of chronic liver diseases and anti-HCV antibodies in two different districts of Saga, Japan. Gastroenterol Jpn 1991;26:157–161.
Nishioka K. Hepatitis C virus infection in Japan. Gastroenterol Jpn 1991;26(Suppl. 3):152–155.
Akahane Y, Takeda K, Okada T, et al. Seroepidemiological survey for clinical significance of NANB-GOR antibodies. The clinical report 1990;24:487–496. (in Japanese)
Garson JA, Tedder RS, Briggs M, et al. Detection of hepatitis C virus sequences in blood donations by “nested” polymerase chain reaction and prediction of infectivity. Lancet 1990;335:1419–1422.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Setoguchi, Y., Yamamoto, K., Ozaki, I. et al. Overlap and discrepancy between tests for anti-C1OO, anti-GOR and anti-CP9 in patients with chronic liver disease and inhabitants in Saga, Japan. Gastroenterol Jpn 27, 502–507 (1992). https://doi.org/10.1007/BF02777786
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02777786